KYTX | tickerfilter.com

Fundamental analysis

21%

Profitability 0%

Dept financing 2%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.56%

1 Month

-26.09%

3 Months

-45.80%

6 Months

-58.54%

1 Year

-92.40%

2 Year

-93.77%

Key data

Stock price

$1.87

P/E Ratio

0.00

DAY RANGE

$1.83 - $2.02

EPS

-$3.33

52 WEEK RANGE

$1.79 - $24.74

52 WEEK CHANGE

-$92.42

MARKET CAP

161.462 M

YIELD

N/A

SHARES OUTSTANDING

43.147 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

1.65

PUBLIC FLOAT

AVERAGE 10 VOLUME

$311,289

AVERAGE 30 VOLUME

$320,670

Company detail

CEO: Peter Maag
Region: US
Website: kyvernatx.com
Employees: 0
IPO year: 2024

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. We were incorporated in Delaware in June 2018 under the name BAIT Therapeutics, Inc., and changed our name to Kyverna Therapeutics, Inc. in October 2019. Our principal executive offices are located at 5980 Horton St., STE 550, Emeryville, CA.

KYTX - Kyverna Therapeutics Inc.